Skip to content

Change in AP at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$409M+581%
Cytokinetics logo
CytokineticsCYTK
$1.52M+133%
PTC Therapeutics logo
PTC TherapeuticsPTCT
-$68.71M-471%
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
-$4.05M+24.9%
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
-$4.8M+44.1%
Viking Therapeutics logo
Viking TherapeuticsVKTX
$13.93M+760%

Other financials

Income statement

See full
Operating income-$54.1M-17.7%
Net income-$49.0M-20.1%
EPS (diluted)-$0.46-7.0%

Balance sheet

See full
Cash & equivalents$33.2M-33.5%
Total debt$3.8M-16.8%
Total equity$493.2M+14.8%
Total assets$518.5M+14.1%

Cash flow

See full
Operating cash flow-$42.5M-12.4%
CapEx$260.0K+491%
Free cash flow-$42.8M-12.9%

Valuation

See full
Market cap$4.18B+61.3%

Returns & leverage

See full
Return on equity-38.1%+13.4pp
Debt / equity0.0×
Current ratio22.6×+1.6×

Where this comes from

Reported directly by Edgewise Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayable.

The official record: Edgewise Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Edgewise Therapeutics, Inc.'s change in ap.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Edgewise Therapeutics, Inc.'s change in AP?
Edgewise Therapeutics, Inc. (EWTX) reported change in AP of $1.45M in Q1 2026.
How has Edgewise Therapeutics, Inc.'s change in AP changed year-over-year?
Edgewise Therapeutics, Inc.'s change in AP decreased by 49.4% year-over-year, from $2.86M to $1.45M.
What does change in AP mean?
Increase or decrease in amounts owed to suppliers — a key working capital component affecting operating cash flow.